Scientists from the University of Birmingham have shown that an existing drug can reduce damage following spinal cord injury, by blocking the inflammatory response in the spinal cord.
Their research, published today in Clinical and translational medicinedemonstrates that AZD1236, a drug developed by AstraZeneca, can significantly reduce “secondary damage” caused by the body’s response to spinal cord injury (SCI).
Researchers led by Professor Zubair Ahmed, Professor of Neuroscience and Head of the Section of Neuroscience and Ophthalmology at the University Institute of Inflammation and Aging, used animal models to demonstrate that AZD1236 can promote significant nerve regeneration, with a dramatic 80% preservation of nerve function following spinal cord compression injury.
Importantly, this resulted in an 85% improvement in movement and sensation. These dramatic effects were observed following just three days of treatment with AZD1236, beginning within 24 hours of injury. Within three weeks, AZD1236-treated animals showed unprecedented recovery, while controls still showed significant deficits six weeks post-injury.
One of the main drivers of secondary SCI damage is the breakdown of the blood-medullary barrier (BSCB). This leads to edema (excess fluid buildup around the spinal cord) and triggers an inflammatory response that can ultimately impede the healing process and lead to nerve cell death.
AZD1236 is a potent and selective inhibitor of two enzymes, MMP-9 and MMP-12, involved in the inflammatory process.
Researchers demonstrated that AZD1236 halts IBS-induced edema and reduces BSCB breakdown and wound healing at the site of injury. They also looked at the effect of AZD1236 dosage on the activity of MMP-9 and MMP-12 in the bloodstream and cerebrospinal fluid, which surrounds the spinal cord.
Here they demonstrated significant suppression of enzyme activity following oral and intrathecal (injection into the spinal canal) administration. Oral administration reduced enzyme activity by 90% in serum and 69-74% in cerebrospinal fluid. Not surprisingly, intrathecal injection produced higher levels (88-90%) of suppression in cerebrospinal fluid.
Other studies have shown that AZD1236 suppresses the formation of pro-inflammatory cytokines (molecules known to contribute to the development of long-lasting neuropathic pain, which often follows spinal cord injury) by 85-95%. AZD1236 was also found to be 82% more effective in relieving IBS-induced neuropathic pain sensitivity to cold, heat, and touch compared to currently used analgesics such as pregabalin (Lyrica) and gabapentin.
Professor Ahmed commented: “There are currently no restorative drugs available for patients with LM, treatments only provide symptomatic relief and do not address the underlying molecular mechanisms that cause or contribute to the disease. edema and rupture of the blood-medullary barrier. This drug has the potential to be a first-in-class treatment once morest some of the key pathological drivers of SCI and might revolutionize the recovery prospects of patients with SCI. »
Hitesh Sanganee, Executive Director, Discovery Sciences, AstraZeneca, said: “The work of Professor Ahmed and his team has been supported by our Open Innovation program and represents a very successful collaboration between academia and industry to bring the possibility of real benefits to affected patients. by SCI, an area of high medical need. Exploring the potential of AZD1236 for this new indication represents an excellent outcome for our open innovation program and aligns with our philosophy of “sharing ideas and enabling scientific innovation to cross borders between the world academia and industry will help translate innovative ideas into scientific breakthroughs and potential new drugs more quickly. »
University of Birmingham Enterprise has filed a patent application covering selective combined inhibitory activity or expression of both matrix metalloproteinase MMP-9 (gelatinase B) and MMP-12 (macrophage metalloelastase) following injury spinal cord or related neurological tissue injury.
The University of Birmingham Enterprise is now seeking investors and partners to move this promising therapeutic into clinical trials.
Source of the story:
Materials provided by University of Birmingham. Note: Content may be edited for style and length.
